Hagen F. Kennecke, MD, MHA, FRCP, medical oncologist, medical director of the Virginia Mason Cancer Institute and current chair of the NCI Rectal-Anal Cancer Task Force, discusses the treatment and screening decision making process for patients with prostate cancer.
Hagen F. Kennecke, MD, MHA, FRCP, medical oncologist, medical director of the Virginia Mason Cancer Institute and current chair of the NCI Rectal-Anal Cancer Task Force, discusses the treatment and screening decision making process for patients with prostate cancer.
There are many treatment options in prostate cancer, says Kennecke, but he would also like to highlight decision aids. These can involve the patient and are offered online by the American Society of Clinical Oncology, the Mayo Clinic, and other major cancer organizations. The decision aids help initiate discussion about not only screening, but Kennecke says 1 of the things that happens is many prostate cancers that are diagnosed are very early stage and may not necessarily require any initial treatment.
Screening and treatment discussions are not as clear with prostate cancer as with others. Treatment is typically required for patients with established high-risk criteria, and the options include surgery or radiation, or both depending on if the tumor is high risk and meets certain criteria.
<< View more resources and information regarding prostate cancer
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen